111 related articles for article (PubMed ID: 30333914)
1. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.
Mizukami T; Kamachi H; Fujii Y; Matsuzawa F; Einama T; Kawamata F; Kobayashi N; Hatanaka Y; Taketomi A
Oncotarget; 2018 Sep; 9(73):33844-33852. PubMed ID: 30333914
[TBL] [Abstract][Full Text] [Related]
2. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Fujii Y; Kamachi H; Matsuzawa F; Mizukami T; Kobayashi N; Fukai M; Taketomi A
Invest New Drugs; 2021 Oct; 39(5):1256-1266. PubMed ID: 33905019
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
4. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
[TBL] [Abstract][Full Text] [Related]
5. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Lindenberg L; Thomas A; Adler S; Mena E; Kurdziel K; Maltzman J; Wallin B; Hoffman K; Pastan I; Paik CH; Choyke P; Hassan R
Oncotarget; 2015 Feb; 6(6):4496-504. PubMed ID: 25756664
[TBL] [Abstract][Full Text] [Related]
6. Amatuximab and novel agents targeting mesothelin for solid tumors.
Baldo P; Cecco S
Onco Targets Ther; 2017; 10():5337-5353. PubMed ID: 29184420
[TBL] [Abstract][Full Text] [Related]
7. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.
Fujisaka Y; Kurata T; Tanaka K; Kudo T; Okamoto K; Tsurutani J; Kaneda H; Okamoto I; Namiki M; Kitamura C; Nakagawa K
Invest New Drugs; 2015 Apr; 33(2):380-8. PubMed ID: 25502863
[TBL] [Abstract][Full Text] [Related]
10. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
[TBL] [Abstract][Full Text] [Related]
11. Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.
Zhao XY; Subramanyam B; Sarapa N; Golfier S; Dinter H
Clin Cancer Drugs; 2016 Oct; 3(2):76-86. PubMed ID: 27853672
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
14.
Montemagno C; Cassim S; Trichanh D; Savary C; Pouyssegur J; Pagès G; Fagret D; Broisat A; Ghezzi C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31658755
[TBL] [Abstract][Full Text] [Related]
15. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.
Benloucif A; Meyer D; Balasse L; Goubard A; Danner L; Bouhlel A; Castellano R; Guillet B; Chames P; Kerfelec B
Front Immunol; 2023; 14():1200652. PubMed ID: 37388728
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
17. Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer.
Sun Q; Zhou S; Zhao J; Deng C; Teng R; Zhao Y; Chen J; Dong J; Yin M; Bai Y; Deng H; Wen J
Oncotarget; 2018 Mar; 9(17):13694-13705. PubMed ID: 29568387
[TBL] [Abstract][Full Text] [Related]
18. Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Sirois AR; Deny DA; Baierl SR; George KS; Moore SJ
PLoS One; 2018; 13(5):e0197029. PubMed ID: 29738555
[TBL] [Abstract][Full Text] [Related]
19. Engineered Fn3 protein has targeted therapeutic effect on mesothelin-expressing cancer cells and increases tumor cell sensitivity to chemotherapy.
Sirois AR; Deny DA; Li Y; Fall YD; Moore SJ
Biotechnol Bioeng; 2020 Feb; 117(2):330-341. PubMed ID: 31631324
[TBL] [Abstract][Full Text] [Related]
20. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.
Zervos E; Agle S; Freistaedter AG; Jones GJ; Roper RL
J Exp Clin Cancer Res; 2016 Mar; 35():39. PubMed ID: 26931187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
